Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Haematological malignancies

3796 - Intensified 14 day rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP14) compared to RCHOP21 in patients with newly diagnosed diffuse large B cell lymphoma (DLBCL): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.


21 Oct 2018


Poster Discussion session - Haematological malignancies


Cytotoxic Therapy

Tumour Site



Jose Sandoval-Sus


Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286


J.D. Sandoval-Sus1, S. Dalia2, R.S. Mhaskar3, J.C. Chavez4, A. Ausekar5, K. Purnapatre5, J. Scheiber5, L. Sokol4

Author affiliations

  • 1 Malignant Hematology, Moffitt Cancer Center, 33028 - Pembroke Pines/US
  • 2 Oncology And Hematology, Mercy Clinic, Joplin/US
  • 3 Internal Medicine, University of South Florida, 33612 - Tampa/US
  • 4 Malignant Hematology, Moffitt Cancer Center, 33612 - Tampa/US
  • 5 Personome, Personome, 80339 - Munich/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3796


Chemoimmunotherapy with RCHOP is the standard frontline treatment for DLBCL based on a 5-year overall survival (OS) of almost 60%. Depending on baseline risk factors, 20%-30% of patients will relapse or have refractory disease. As such, intensified regimens such as RCHOP14 are being used. But evidence of effectiveness and toxicity of RCHOP14 versus RCHOP21 is scarce.


In this systematic review and meta analysis conducted per Cochrane guidelines we included all RCTs addressing clinical outcomes and toxicity of dose intensification (RCHOP 14) versus RCHOP 21 regimens in patients with DLBCL. Data were pooled and reported as hazard ratio (HR) or risk ratio (RR) under a random-effects model and reported with 95% confidence intervals (95% CIs).


We included four RCTs enrolling 2956 patients. Pooled results showed no difference between RCHOP 14 and RCHOP 21 regimens for OS (HR 0.92, 95% CI 0.77 to 1.09) and progression free survival (PFS) (HR 0.96, 95% CI 0.82 to 1.12).RCHOP 21 regimen achieved higher rates of complete responses (CR) compared to RCHOP 14(RR 1.15, 95% CI 1.06 to 1.25; I2 0%, 4 RCTs). There were no differences between RCHOP 14 and RCHOP 21 regimens for pooled estimates of treatment related mortality (RR 1.49, 95% CI 0.51 to 4.30), febrile neutropenia (RR 0.76, 95% CI 0.32 to 1.80), neutropenia (RR 0.78, 95% CI 0.36 to 1.67), thrombocytopenia (RR 1.18, 95% CI 0.54 to 2.58), cardiotoxicity (RR 1.33, 95% CI 0.09 to 19.59), and peripheral neuropathy (RR 1.26, 95% CI 0.90 to 1.79). Overall methodological quality of included studies was moderate due to publication bias and imprecision.


The results of this meta-analysis showed that RCHOP14 regimen in patients with DLBCL achieved lower CR rates compared to RCHOP21. However, both regimens were similar in terms of PFS, OS and grade 3 or 4 toxicities. These results suggest that the efficacy and safety of both regimens are comparable, and that R-CHOP14 remains a viable option in patients who prefer a shorter therapy course. Further analyses are needed to assess the cost differences between both chemotherapies.

Clinical trial identification

Legal entity responsible for the study

Moffitt Cancer Center.

Editorial Acknowledgement


A. Ausekar: CEO, major shareholder and member of the Board of Directors: Personome Life Sciences. K. Purnapatre: Head of research: Personome Life Sciences. J. Scheiber: Founder and major shareholder: Biovariance; Scientific advisor: Personome Life Sciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.